Basic Information
RNALocate ID: | RLID:11001713 |
RNA Symbol: | hsa-miR-124-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-124-3p |
RNA ID: | miRBase:MIMAT0000422 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001752 | Mitochondrion | Cell line (HEK-293) | 22984580 |
RLID:11001714 | Microvesicle | Cerebrospinal fluid | 24797360 |
RLID-D:11000075 | Exosome | Blood | |
RLID-D:11000350 | Microvesicle | Blood|Fibroblasts|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-124-3p | Inflammatory bowel disease | MNDR-E-MI-06103 |
MNDR | hsa-miR-124-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-06104 |
MNDR | hsa-miR-124-3p | Oral squamous cell carcinoma | MNDR-E-MI-06105 |
MNDR | hsa-miR-124-3p | Medulloblastoma | MNDR-E-MI-06106 |
MNDR | hsa-miR-124-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-06107 |
MNDR | hsa-miR-124-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-06108 |
MNDR | hsa-miR-124-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-06109 |
MNDR | hsa-miR-124-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-06110 |
MNDR | hsa-miR-124-3p | Her2-receptor positive breast cancer | MNDR-E-MI-06111 |
MNDR | hsa-miR-124-3p | Anencephaly | MNDR-E-MI-06112 |
MNDR | hsa-miR-124-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-06113 |
MNDR | hsa-miR-124-3p | Lupus nephritis | MNDR-E-MI-06114 |
MNDR | hsa-miR-124-3p | Prostate cancer | MNDR-E-MI-06115 |
MNDR | hsa-miR-124-3p | Chronic lymphocytic leukemia | MNDR-E-MI-06116 |
MNDR | hsa-miR-124-3p | Gastric cancer | MNDR-E-MI-06117 |
MNDR | hsa-miR-124-3p | Alzheimer disease | MNDR-E-MI-06118 |
MNDR | hsa-miR-124-3p | Bladder cancer | MNDR-E-MI-06119 |
MNDR | hsa-miR-124-3p | Dysautonomia familial | MNDR-E-MI-06120 |
MNDR | hsa-miR-124-3p | Seizures | MNDR-E-MI-06121 |
MNDR | hsa-miR-124-3p | Friedreich ataxia | MNDR-E-MI-06122 |
MNDR | hsa-miR-124-3p | Huntington disease | MNDR-E-MI-06123 |
MNDR | hsa-miR-124-3p | Chorea | MNDR-E-MI-06124 |
MNDR | hsa-miR-124-3p | Cardiovascular disease | MNDR-E-MI-06125 |
MNDR | hsa-miR-124-3p | Brain cancer | MNDR-E-MI-06126 |
MNDR | hsa-miR-124-3p | Lung cancer | MNDR-E-MI-06127 |
MNDR | hsa-miR-124-3p | Fragile x syndrome | MNDR-E-MI-06128 |
MNDR | hsa-miR-124-3p | Parkinson disease | MNDR-E-MI-06129 |
MNDR | hsa-miR-124-3p | Major depressive disorder | MNDR-E-MI-06130 |
MNDR | hsa-miR-124-3p | Depression | MNDR-E-MI-06131 |
MNDR | hsa-miR-124-3p | Breast cancer | MNDR-E-MI-06132 |
MNDR | hsa-miR-124-3p | Cancer | MNDR-E-MI-06133 |
MNDR | hsa-miR-124-3p | Thyroid cancer | MNDR-E-MI-06134 |
MNDR | hsa-miR-124-3p | Pituitary neoplasms | MNDR-E-MI-06135 |
MNDR | hsa-miR-124-3p | Pancreatic cancer | MNDR-E-MI-06136 |
MNDR | hsa-miR-124-3p | Hepatitis C | MNDR-E-MI-06137 |
MNDR | hsa-miR-124-3p | Melanoma | MNDR-E-MI-06138 |
MNDR | hsa-miR-124-3p | Nephroblastoma | MNDR-E-MI-06139 |
MNDR | hsa-miR-124-3p | Colon cancer | MNDR-E-MI-06140 |
MNDR | hsa-miR-124-3p | Ischemic attack transient | MNDR-E-MI-06141 |
MNDR | hsa-miR-124-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-06142 |
MNDR | hsa-miR-124-3p | Familial ovarian cancer | MNDR-E-MI-06143 |
MNDR | hsa-miR-124-3p | Acromegaly | MNDR-E-MI-06144 |
MNDR | hsa-miR-124-3p | Kidney cancer | MNDR-E-MI-06145 |
MNDR | hsa-miR-124-3p | Cerebellar disease | MNDR-E-MI-06146 |
MNDR | hsa-miR-124-3p | Glioblastoma | MNDR-E-MI-06147 |
MNDR | hsa-miR-124-3p | Astrocytoma | MNDR-E-MI-06148 |
MNDR | hsa-miR-124-3p | Glioma | MNDR-E-MI-06149 |
MNDR | hsa-miR-124-3p | Oligodendroglioma | MNDR-E-MI-06150 |
MNDR | hsa-miR-124-3p | Teratocarcinoma | MNDR-E-MI-06151 |
MNDR | hsa-miR-124-3p | Central nervous system disease | MNDR-E-MI-06152 |
MNDR | hsa-miR-124-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-06153 |
MNDR | hsa-miR-124-3p | Epilepsy temporal lobe | MNDR-E-MI-06154 |
MNDR | hsa-miR-124-3p | Osteosarcoma | MNDR-E-MI-06155 |
MNDR | hsa-miR-124-3p | Ewing sarcoma | MNDR-E-MI-06156 |
MNDR | hsa-miR-124-3p | Pancreatic duct adenocarcinoma | MNDR-E-MI-06157 |
MNDR | hsa-miR-124-3p | Meningioma | MNDR-E-MI-06158 |
MNDR | hsa-miR-124-3p | Liver cancer | MNDR-E-MI-06159 |
MNDR | hsa-miR-124-3p | Pituitary adenoma | MNDR-E-MI-06160 |
MNDR | hsa-miR-124-3p | Carcinoma lung non-small-cell | MNDR-E-MI-06161 |
MNDR | hsa-miR-124-3p | Lung adenocarcinoma | MNDR-E-MI-06162 |
MNDR | hsa-miR-124-3p | Papillary thyroid carcinoma | MNDR-E-MI-06163 |
MNDR | hsa-miR-124-3p | Cervical cancer | MNDR-E-MI-06164 |
MNDR | hsa-miR-124-3p | Renal cell carcinoma | MNDR-E-MI-06165 |
MNDR | hsa-miR-124-3p | Renal clear cell carcinoma | MNDR-E-MI-06166 |
MNDR | hsa-miR-124-3p | Biliary tract cancer | MNDR-E-MI-06167 |
MNDR | hsa-miR-124-3p | Neoplasms of the small intestine | MNDR-E-MI-06168 |
MNDR | hsa-miR-124-3p | Cholangiocarcinoma | MNDR-E-MI-06169 |
MNDR | hsa-miR-124-3p | Esophageal cancer | MNDR-E-MI-06170 |
MNDR | hsa-miR-124-3p | Lung small cell carcinoma | MNDR-E-MI-06171 |
MNDR | hsa-miR-124-3p | Encephalopathy bovine spongiform | MNDR-E-MI-06172 |
MNDR | hsa-miR-124-3p | Uveal melanoma | MNDR-E-MI-06173 |
MNDR | hsa-miR-124-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-06174 |
MNDR | hsa-miR-124-3p | Bladder transitional cell carcinoma | MNDR-E-MI-06175 |
MNDR | hsa-miR-124-3p | Progressive supranuclear palsy | MNDR-E-MI-06176 |
MNDR | hsa-miR-124-3p | Hepatocellular carcinoma | MNDR-E-MI-06177 |
MNDR | hsa-miR-124-3p | Familiar ovarian carcinoma | MNDR-E-MI-06178 |
MNDR | hsa-miR-124-3p | B-cell lymphoma | MNDR-E-MI-06179 |
MNDR | hsa-miR-124-3p | Retinoblastoma | MNDR-E-MI-06180 |
MNDR | hsa-miR-124-3p | Neuroblastoma | MNDR-E-MI-06181 |
MNDR | hsa-miR-124-3p | Barrett's adenocarcinoma | MNDR-E-MI-06182 |
MNDR | hsa-miR-124-3p | Hodgkin lymphoma | MNDR-E-MI-06183 |
MNDR | hsa-miR-124-3p | Tongue cancer | MNDR-E-MI-06184 |
MNDR | hsa-miR-124-3p | Ritter's disease | MNDR-E-MI-06185 |
MNDR | hsa-miR-124-3p | Acute myelogenous leukemia | MNDR-E-MI-06186 |
MNDR | hsa-miR-124-3p | Colorectal cancer | MNDR-E-MI-06187 |
MNDR | hsa-miR-124-3p | Nasopharyngeal carcinoma | MNDR-E-MI-06188 |
MNDR | hsa-miR-124-3p | Type 2 diabetes mellitus | MNDR-E-MI-06189 |
MNDR | hsa-miR-124-3p | Multiple myeloma | MNDR-E-MI-06190 |
MNDR | hsa-miR-124-3p | Nasopharyngeal carcinoma | MNDR-E-MI-06191 |
MNDR | hsa-miR-124-3p | Leukemia lymphoblastic acute | MNDR-E-MI-06192 |
MNDR | hsa-miR-124-3p | Ovarian epithelial cancer | MNDR-E-MI-06193 |
MNDR | hsa-miR-124-3p | Uterine cervical neoplasms | MNDR-E-MI-06194 |
MNDR | hsa-miR-124-3p | Ependymoma | MNDR-E-MI-06195 |
MNDR | hsa-miR-124-3p | Prostatic neoplasms | MNDR-E-MI-06196 |
MNDR | hsa-miR-124-3p | Gait ataxia | MNDR-E-MI-06197 |
MNDR | hsa-miR-124-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-06198 |
MNDR | hsa-miR-124-3p | Stroke lacunar | MNDR-E-MI-06199 |
MNDR | hsa-miR-124-3p | Barrett's carcinogenesis | MNDR-E-MI-06200 |
MNDR | hsa-miR-124-3p | Breast cancer her3+ negative | MNDR-E-MI-06201 |
MNDR | hsa-miR-124-3p | Cerebellar neurodegeneration | MNDR-E-MI-06202 |
MNDR | hsa-miR-124-3p | Cholestatic liver injury | MNDR-E-MI-06203 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABHD4 | Homo sapiens | RR00026289 |
TOP